J&J Appoints Head Of Innovation London
This article was originally published in Scrip
Johnson & Johnson has appointed Richard Mason head of its London Innovation Centre. Most recently, Mason was CEO of XO1 Ltd. which was acquired through a J&J innovation-facilitated deal this year. Prior to this, he was head of strategy and business development at BTG PLC. and he has also previously held senior management positions for Advent Venture Partners LLC. where he was interim CEO for various portfolio companies. Mason also led business development at Cambridge Antibody Technology.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.